Mark Jeffrey DeLong - 11 Feb 2026 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role
Chief Business & Strat Officer
Signature
/s/ David Watson, attorney-in-fact for Mark DeLong
Issuer symbol
APLS
Transactions as of
11 Feb 2026
Net transactions value
-$8,153
Form type
4
Filing time
13 Feb 2026, 09:23:44 UTC
Previous filing
30 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
DeLong Mark Jeffrey Chief Business & Strat Officer C/O APELLIS PHARMACEUTICALS, INC., 100 FIFTH AVENUE, 3RD FLOOR, WALTHAM /s/ David Watson, attorney-in-fact for Mark DeLong 13 Feb 2026 0001856078

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APLS Common Stock Sale $8,153 -368 -0.32% $22.15 114,591 11 Feb 2026 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This represents shares sold to cover tax withholding on the Restricted Stock Units released on February 10, 2026.